Media coverage about Progenics Pharmaceuticals (NASDAQ:PGNX) has been trending somewhat positive on Thursday, Accern Sentiment reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Progenics Pharmaceuticals earned a news impact score of 0.15 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.9066592402204 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
A number of equities analysts have weighed in on the company. BidaskClub raised Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 14th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $15.00 price target on shares of Progenics Pharmaceuticals in a research report on Wednesday, January 17th. ValuEngine lowered shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 16th. Finally, Zacks Investment Research lowered shares of Progenics Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, January 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $12.35.
Shares of Progenics Pharmaceuticals (NASDAQ:PGNX) opened at $5.84 on Thursday. Progenics Pharmaceuticals has a 52-week low of $4.60 and a 52-week high of $11.72. The company has a market cap of $410.38, a PE ratio of -7.39 and a beta of 3.40. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.86 and a current ratio of 7.86.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.